85 related articles for article (PubMed ID: 24762994)
21. The association of aberrant folylpolyglutamate synthetase splicing with ex vivo methotrexate resistance and clinical outcome in childhood acute lymphoblastic leukemia.
Wojtuszkiewicz A; Assaraf YG; Hoekstra M; Sciarrillo R; Jansen G; Peters GJ; Pieters R; Sonneveld E; Escherich G; Kaspers GJ; Cloos J
Haematologica; 2016 Jul; 101(7):e291-4. PubMed ID: 27036162
[No Abstract] [Full Text] [Related]
22. Impact of genotype on survival of children with T-cell acute lymphoblastic leukemia treated according to the French protocol FRALLE-93: the effect of TLX3/HOX11L2 gene expression on outcome.
Ballerini P; Landman-Parker J; Cayuela JM; Asnafi V; Labopin M; Gandemer V; Perel Y; Michel G; Leblanc T; Schmitt C; Fasola S; Hagemejier A; Sigaux F; Auclerc MF; Douay L; Leverger G; Baruchel A
Haematologica; 2008 Nov; 93(11):1658-65. PubMed ID: 18835836
[TBL] [Abstract][Full Text] [Related]
23. [Relationship between the methylenetetrahydrofolate reductase gene polymorphism and adverse reactions of high-dose methotrexate in children with acute lymphocytic leukemia].
Zheng MM; Yue LJ; Chen XW; Wen FQ; Li CG; Yang CL; Xie C; Ding H
Zhongguo Dang Dai Er Ke Za Zhi; 2013 Mar; 15(3):201-6. PubMed ID: 23498762
[TBL] [Abstract][Full Text] [Related]
24. Exploratory analysis of four polymorphisms in human GGH and FPGS genes and their effect in methotrexate-treated rheumatoid arthritis patients.
van der Straaten RJ; Wessels JA; de Vries-Bouwstra JK; Goekoop-Ruiterman YP; Allaart CF; Bogaartz J; Tiller M; Huizinga TW; Guchelaar HJ
Pharmacogenomics; 2007 Feb; 8(2):141-50. PubMed ID: 17286537
[TBL] [Abstract][Full Text] [Related]
25. MTHFR 677 (C-->T) polymorphism is not relevant for prognosis or therapy-associated toxicity in pediatric NHL: results from 484 patients of multicenter trial NHL-BFM 95.
Seidemann K; Book M; Zimmermann M; Meyer U; Welte K; Stanulla M; Reiter A
Ann Hematol; 2006 May; 85(5):291-300. PubMed ID: 16463153
[TBL] [Abstract][Full Text] [Related]
26. Methotrexate consolidation treatment according to pharmacogenetics of MTHFR ameliorates event-free survival in childhood acute lymphoblastic leukaemia.
Salazar J; Altés A; del Río E; Estella J; Rives S; Tasso M; Navajas A; Molina J; Villa M; Vivanco JL; Torrent M; Baiget M; Badell I
Pharmacogenomics J; 2012 Oct; 12(5):379-85. PubMed ID: 21747412
[TBL] [Abstract][Full Text] [Related]
27. Development and Validation of a Sensitive UHPLC-MS/MS-Based Method for the Analysis of Folylpolyglutamate Synthetase Enzymatic Activity in Peripheral Blood Mononuclear Cells: Application in Rheumatoid Arthritis and Leukemia Patients.
Muller IB; Lin M; Struys EA; Heydari P; Hebing RCF; Nurmohamed MT; van der Laken C; Lems WF; Cloos J; Jansen G; de Jonge R
Ther Drug Monit; 2019 Oct; 41(5):598-606. PubMed ID: 31008996
[TBL] [Abstract][Full Text] [Related]
28. Polymorphism G80A in the reduced folate carrier gene and its relationship to survival and risk of relapse in acute lymphoblastic leukemia.
Leyva-Vázquez MA; Organista-Nava J; Gómez-Gómez Y; Contreras-Quiroz A; Flores-Alfaro E; Illades-Aguiar B
J Investig Med; 2012 Oct; 60(7):1064-7. PubMed ID: 22914600
[TBL] [Abstract][Full Text] [Related]
29. Differences in constitutive and post-methotrexate folylpolyglutamate synthetase activity in B-lineage and T-lineage leukemia.
Barredo JC; Synold TW; Laver J; Relling MV; Pui CH; Priest DG; Evans WE
Blood; 1994 Jul; 84(2):564-9. PubMed ID: 7517720
[TBL] [Abstract][Full Text] [Related]
30. The circadian schedule for childhood acute lymphoblastic leukemia maintenance therapy does not influence event-free survival in the NOPHO ALL92 protocol.
Clemmensen KK; Christensen RH; Shabaneh DN; Harila-Saari A; Heyman M; Jonsson OG; Wesenberg F; Rosthøj S; Schmiegelow K;
Pediatr Blood Cancer; 2014 Apr; 61(4):653-8. PubMed ID: 24265159
[TBL] [Abstract][Full Text] [Related]
31. Association of -24CT, 1249GA, and 3972CT ABCC2 gene polymorphisms with methotrexate serum levels and toxic side effects in children with acute lymphoblastic leukemia.
Sharifi MJ; Bahoush G; Zaker F; Ansari S; Rafsanjani KA; Sharafi H
Pediatr Hematol Oncol; 2014 Mar; 31(2):169-77. PubMed ID: 24552501
[TBL] [Abstract][Full Text] [Related]
32. Polymorphisms in the methotrexate transport pathway: a new tool for MTX plasma level prediction in pediatric acute lymphoblastic leukemia.
Lopez-Lopez E; Ballesteros J; Piñan MA; Sanchez de Toledo J; Garcia de Andoin N; Garcia-Miguel P; Navajas A; Garcia-Orad A
Pharmacogenet Genomics; 2013 Feb; 23(2):53-61. PubMed ID: 23222202
[TBL] [Abstract][Full Text] [Related]
33. C677T and A1298C polymorphisms of the methylenetetrahydrofolate reductase gene: effect on methotrexate-related toxicity in adult acute lymphoblastic leukaemia.
Eissa DS; Ahmed TM
Blood Coagul Fibrinolysis; 2013 Mar; 24(2):181-8. PubMed ID: 23183238
[TBL] [Abstract][Full Text] [Related]
34. [Monitoring of minimal residual disease in children with acute lymphoblastic leukemia and its prognostic significance].
Xu XJ; Tang YM; Song H; Shi SW; Yang SL; Shen HQ; Wei J; Xu WQ; Pan BH; Zhao FY
Zhonghua Er Ke Za Zhi; 2010 Mar; 48(3):180-4. PubMed ID: 20426951
[TBL] [Abstract][Full Text] [Related]
35. [Analysis of clinical features and prognostic significance of childhood T-lineage acute lymphoblastic leukemia].
Zhang YL; Zhao WL; Nie SS; Guo DD; Ji ZH; Chai YH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Dec; 19(6):1496-500. PubMed ID: 22169311
[TBL] [Abstract][Full Text] [Related]
36. Methotrexate resistance in relation to treatment outcome in childhood acute lymphoblastic leukemia.
Wojtuszkiewicz A; Peters GJ; van Woerden NL; Dubbelman B; Escherich G; Schmiegelow K; Sonneveld E; Pieters R; van de Ven PM; Jansen G; Assaraf YG; Kaspers GJ; Cloos J
J Hematol Oncol; 2015 May; 8():61. PubMed ID: 26022503
[TBL] [Abstract][Full Text] [Related]
37. Asparagine synthetase (ASNS) gene polymorphism is associated with the outcome of childhood acute lymphoblastic leukemia by affecting early response to treatment.
Pastorczak A; Fendler W; Zalewska-Szewczyk B; Górniak P; Lejman M; Trelińska J; Walenciak J; Kowalczyk J; Szczepanski T; Mlynarski W;
Leuk Res; 2014 Feb; 38(2):180-3. PubMed ID: 24268318
[TBL] [Abstract][Full Text] [Related]
38. High-dose methotrexate therapy of childhood acute lymphoblastic leukemia: lack of relation between serum methotrexate concentration and creatinine clearance.
Joannon P; Oviedo I; Campbell M; Tordecilla J
Pediatr Blood Cancer; 2004 Jul; 43(1):17-22. PubMed ID: 15170885
[TBL] [Abstract][Full Text] [Related]
39. MTHFR polymorphisms' influence on outcome and toxicity in acute lymphoblastic leukemia patients.
Chiusolo P; Reddiconto G; Farina G; Mannocci A; Fiorini A; Palladino M; La Torre G; Fianchi L; Sorà F; Laurenti L; Leone G; Sica S
Leuk Res; 2007 Dec; 31(12):1669-74. PubMed ID: 17512587
[TBL] [Abstract][Full Text] [Related]
40. Folate cycle gene variants and chemotherapy toxicity in pediatric patients with acute lymphoblastic leukemia.
Costea I; Moghrabi A; Laverdiere C; Graziani A; Krajinovic M
Haematologica; 2006 Aug; 91(8):1113-6. PubMed ID: 16870553
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
